TrialThe New England journal of medicine2021
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.
Robert Motzer et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
994 papers cite itlatest 60 shown
this paperpooled ittrialcites it